Evidence map›Paper›PMID 28928823›Full record

ArticleOncology letters2017

Experimental study of a novel tumstatin on C6 brain glioma

Pengguo Zhang, Qingwei Zhou, Lin Tian, Xiangyu Zhou, Yue Zhou, Jiajun Chen

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Pengguo ZhangDepartment of Radiology, Jilin University Second Hospital, Changchun, Jilin 130022, P.R. China.
Qingwei ZhouDepartment of Biology and Medical Engineering, School of Regenerative Medicine, Jilin University, Changchun, Jilin 130022, P.R. China.
Lin TianDepartment of Biology and Medical Engineering, School of Pharmacy, Jilin University, Changchun, Jilin 130022, P.R. China.
Xiangyu ZhouDepartment of Neurology, China-Japan Union Hospital, Jilin University, Changchun, Jilin 130022, P.R. China.
Yue ZhouDepartment of Biological Preparation, School of Pharmacy, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210046, P.R. China.
Jiajun ChenDepartment of Neurology, China-Japan Union Hospital, Jilin University, Changchun, Jilin 130022, P.R. China.
Jilin University · CNNanjing University · CNSecond Affiliated Hospital of Jilin University · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the effect of a novel tumstatin on C6 brain glioma cells, the MTT method was used to detect C6 glioma cell proliferation activity at different time periods (12, 48 and 72 h). Cell cycle distribution and apoptosis rate were detected by flow cytometry, and the acridine orange/ethidium bromide staining method was used to detect apoptosis and mitochondrial membrane potential by fluorescence microscopy. Novel tumstatin had an evident inhibitory effect on C6 glioma cells, and the most notable impact emerged after 48 h. The following were observed under the fluorescence microscope: Characteristic morphological changes of cell apoptosis were typically observed in the novel tumstatin (2,000 µg/ml) group; mitochondrial membrane potential decreased significantly (P<0.05); the cells in the G0/G1 phase significantly increased (P<0.05); and the number of cells in the S phase was reduced. There was an increase in cell apoptosis rate in the novel tumstatin (2,000 µg/ml) group compared with the novel tumstatin (1,000 µg/ml) group and the Mock group, and the data were statistically significant (P<0.05). Novel tumstatin may reduce the mitochondrial membrane potential, inducing cell apoptosis, and thereby exerting antitumor activity.

Indexed as

C6 glioma cellcell apoptosisflow cytometrynovel tumstatin

Identifiers

PMID28928823
PMCPMC5588131
OpenAlexW2732089902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.